BETAAccess all features while we're in beta! Some features may become paid later.Got feedback? Reach us 👉

Loading AYTU charts…

Search ticker or company⌘K

AYTU

01Multicharts 02Comparables 03Price target

May we use analytics cookies to see how vpside is used, including anonymous session recordings? Accepting also loads the price chart, which sets its own cookies. Essential cookies are always on. Privacy

AYTU · Aytu Biopharma, Inc. fundamentals · vpside

vpside

⌘K

AYTULast filing 10-K, FY26 · 22 Sept 2026/AYTULast filing 10-K, FY26 · 22 Sept 2026/AYTULast filing 10-K, FY26 · 22 Sept 2026/AYTULast filing 10-K, FY26 · 22 Sept 2026/

Filings synced 13:22

AYTU

Aytu Biopharma, Inc.

Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 30 Jun

01Multicharts 02Comparables 03Price target

Add a metric37 metrics

Revenue, quarterly

$16M+6.4% year on year

$40M$20M$0

vpside.com

Q1 ’22Q2 ’23Q3 ’24Q3 ’25Q4 ’26

Company filings · 10-K filed 22 Sept 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

64.0%−5.1 pp year on year

80%60%40%

vpside.com

Q1 ’22Q2 ’23Q3 ’24Q3 ’25Q4 ’26

Company filings · 10-K filed 22 Sept 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$26M−15.0% year on year

$60M$40M$20M$0

vpside.com

Q1 ’22Q2 ’23Q3 ’24Q3 ’25Q4 ’26

Company filings · 10-K filed 22 Sept 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

$3M

$4M$2M$0−$2M−$4M

vpside.com

Q1 ’22Q2 ’23Q3 ’24Q3 ’25Q4 ’26

Company filings · 10-K filed 22 Sept 2026 · TTM = last four quartersvpside.com

Chart 05 is empty

Chart 06 is empty

Fundamentals: company filings · Q4 = full year − nine months · TTM = last four quarters